Teriparatide and abaloparatide are both FDA-approved anabolic (bone-building) osteoporosis drugs — a different approach from drugs that merely slow bone loss. Teriparatide is recombinant parathyroid hormone (PTH 1–34); abaloparatide is an analog of PTH-related protein (PTHrP). Both are daily self-injections that stimulate new bone formation.
At a glance
| Teriparatide | Abaloparatide | |
|---|---|---|
| Class | Recombinant PTH (1–34) | PTHrP analog |
| Brand name | Forteo | Tymlos |
| FDA status | Approved | Approved |
| Action | Anabolic — builds new bone | Anabolic — builds new bone |
| Dosing | Once-daily injection | Once-daily injection |
| Generation | Earlier anabolic agent | Newer anabolic agent |
The bottom line
Bottom line: Both are genuine bone-builders for osteoporosis — a category apart from antiresorptive drugs — and both are approved daily injections. Teriparatide (PTH-based) is the longer-established agent; abaloparatide (PTHrP-based) is newer. The choice between them is a clinical one based on individual risk and response.
Frequently asked questions
What's the difference between teriparatide and abaloparatide?
Both are anabolic osteoporosis drugs given as daily injections, but teriparatide is recombinant parathyroid hormone (PTH 1–34) while abaloparatide is an analog of PTH-related protein (PTHrP). Both stimulate new bone formation.
Are both FDA-approved?
Yes. Both teriparatide (Forteo) and abaloparatide (Tymlos) are FDA-approved anabolic agents for osteoporosis in people at high risk of fracture, used under medical supervision.
How are anabolic osteoporosis drugs different from other treatments?
Anabolic agents like these actively build new bone, whereas antiresorptive drugs (such as bisphosphonates) mainly slow bone loss. They are typically reserved for higher-risk patients.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001. Peer-reviewed study
- Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human PTH(1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003. Peer-reviewed study
- Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015. Peer-reviewed study
- Li M, Ge Z, Zhang B, et al. Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos. 2024. Peer-reviewed study
- Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther. 2004. Peer-reviewed study
- Yuan F, Peng W, Yang C, et al. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis. Int J Surg. 2019. Peer-reviewed study
- Miller PD, Hattersley G, Riis BJ, et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis (ACTIVE): A Randomized Clinical Trial. JAMA. 2016. Peer-reviewed study
- Cosman F, Miller PD, Williams GC, et al. Abaloparatide followed by alendronate in postmenopausal osteoporosis (ACTIVExtend). Mayo Clin Proc. 2017. Peer-reviewed study
- Ebina K, Etani Y, Noguchi T, et al. Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis. J Bone Miner Metab. 2025. Peer-reviewed study
- Gonnelli S, Caffarelli C. Abaloparatide. Clin Cases Miner Bone Metab. 2016. Peer-reviewed study
- Sleeman A, Clements JN. Abaloparatide: A new pharmacological option for osteoporosis. Am J Health Syst Pharm. 2019. Peer-reviewed study
- Thompson JC, Wanderman N, Anderson PA, et al. Abaloparatide and the Spine: A Narrative Review. Clin Interv Aging. 2020. Peer-reviewed study